Management of Intrahepatic Cholestasis of Pregnancy with Bile Acids ≥100 μmol/L

Introduction to Management

The American College of Obstetricians and Gynecologists recommends delivery at 36 0/7 weeks of gestation for patients with bile acid levels ≥100 μmol/L, as this represents a critical threshold where stillbirth risk increases substantially (hazard ratio 30.50) 1, 2, 3

The Society for Maternal-Fetal Medicine suggests initiating ursodeoxycholic acid (UDCA) at 10-15 mg/kg/day as first-line treatment to reduce maternal pruritus and potentially improve perinatal outcomes, though evidence for fetal benefit is mixed 4, 5
Titrate UDCA up to maximum 21-25 mg/kg/day if pruritus remains uncontrolled after initial dosing, as recommended by the American College of Obstetricians and Gynecologists 6
Expect clinical improvement in pruritus within 1-2 weeks and biochemical improvement within 3-4 weeks of UDCA initiation, according to the American College of Obstetricians and Gynecologists 7, 6

The American College of Obstetricians and Gynecologists recommends initiating antenatal fetal surveillance immediately at the time of diagnosis, given the substantially elevated stillbirth risk at bile acid levels ≥100 μmol/L 7
Increase frequency of fetal monitoring compared to lower bile acid levels—consider twice-weekly or more frequent testing given the 30-fold increased stillbirth hazard, as suggested by the Society for Maternal-Fetal Medicine 7, 4

For bile acids ≥100 μmol/L, the American College of Obstetricians and Gynecologists recommends delivering at 36 0/7 weeks of gestation or at time of diagnosis if already beyond 36 weeks 1, 2, 3, 6
Consider earlier delivery (34-36 weeks) if any of the following are present: excruciating and unremitting maternal pruritus despite maximum pharmacotherapy, history of prior stillbirth before 36 weeks due to ICP with recurrence in current pregnancy, or preexisting or acute hepatic disease with worsening hepatic function, as recommended by the American College of Obstetricians and Gynecologists 1, 2, 3

The American College of Obstetricians and Gynecologists suggests monitoring for preeclampsia development, as ICP patients have 2.6-fold increased risk, typically occurring 2-4 weeks after ICP diagnosis 4, 5

Discontinue UDCA at delivery, as recommended by the American College of Obstetricians and Gynecologists 6
Repeat biochemical testing if symptoms persist 4-6 weeks postpartum, and refer to hepatology if abnormalities continue, according to the American College of Obstetricians and Gynecologists 7, 6
Counsel about 90% recurrence risk in future pregnancies, as suggested by the American College of Obstetricians and Gynecologists 1, 3